ChemoMetec A/S (FRA:CHY)

Market Cap	1.16B -5.8%
Revenue (ttm)	66.03M +7.3%
Net Income	23.70M +4.7%
EPS	1.36 +4.6%
Shares Out	n/a
PE Ratio	48.79
Forward PE	40.81
Dividend	0.94 (1.49%)
Ex-Dividend Date	Oct 10, 2025

Volume	n/a
Open	66.00
Previous Close	64.80
Day's Range	66.00 - 66.00
52-Week Range	33.74 - 106.60
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 10, 2026

About ChemoMetec

ChemoMetec A/S engages in the development, production, and sale of analytical equipment for cell counting and analysis the United States, Canada, Europe, and internationally. The company offers its solutions in the areas of cell and gene therapy, cancer and stem cell research, and development and manufacturing of pharmaceuticals, as well as production and quality control of animal semen, milk, and beer. Its products include NucleoCounter NC-3000, an advanced image cytometer; NucleoCounter NC-250, an automated cell analyzer; NucleoCounter NC-202...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1997
• Employees: 172
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: CHY

Financial Performance

In fiscal year 2025, ChemoMetec's revenue was 495.57 million, an increase of 21.50% compared to the previous year's 407.87 million. Earnings were 186.41 million, an increase of 36.78%.

Financial numbers in DKK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error